Management was competent enough to have a financial back-up plan in the event an EUA was not approved.
And I would say that applies to developing an alternate revenue stream, also, through Clinigen.
Something has led to Humanigen becoming more resilient, and less fragile. I doubt that is because the company is going to accept a tender offering.
I'm really confident that the company has transitioned to becoming a revenue-funded entity.
And still, I have not seen a competitive product come onto the market designed to treat hospitalized and hypoxic patients, and certainly not one that even approaches lenzilumab's efficacy.
To date, there have been almost 9B vaccinations, 1B just in the last month. There's been no relief on hospitals and medical staff.
Lenz will provide that relief. Our market prospects look better to me now than they ever have.
Merry Christmas to you, as well, 10nisman.
News 
Market Data 
Discover 
